13th U.S. AI patent awarded to Mauna Kea

Expanded patent portfolio boosts platform value, supports strategic partnerships

Regulatory News:

Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced that it has been granted a new U.S. patent for real-time AI-based enhancement of Confocal Laser Endomicroscopy (CLE), significantly reinforcing its intellectual property.

This new technology represents an innovative solution for interfacing a real-time AI-assisted version of Cellvizio with physicians, taking into account the cognitive and user experience constraints specific to diagnostic procedures. This cutting-edge technology aims to improve user experience and efficiency of AI-integrated endomicroscopy in clinical settings.

This new patent1, codenamed “AURA”, complements Mauna Kea's existing "EVA" (Endomicroscopy Virtual Assistant) portfolio, which already comprises 12 patents dedicated to AI-based innovative multistage image processing architectures and workflows.

The combined capabilities of AURA and EVA are expected to significantly enhance the usability, interface, and effectiveness of Mauna Kea's Cellvizio CLE technology, improving physicians’ ability to adopt and use Cellvizio across various medical specialties. This achievement builds on Mauna Kea's recent partnership with the UK-based company V7, a leading AI and data labeling company, announced in March 2024, which focuses on building large, high-quality annotated endomicroscopy datasets.

Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies commented: "Since the launch of Cellvizio, Mauna Kea has strategically invested in machine learning capabilities - including the “Smart Atlas” project in 2010 - and its related intellectual property. We are making significant progress on our AI roadmap and obtaining our 13th patent on this key topic is a major and timely milestone. The synergy between our expanding patent portfolio, including AURA and EVA, and our recent partnerships creates a rich ecosystem for advancing AI, in multiple therapeutic areas, including early-stage esophageal cancer detection, pancreatic cyst characterization and Inflammatory Bowel Disease. This approach positions Mauna Kea at the forefront of AI-assisted in vivo cellular imaging enabling improved treatment and outcomes."

***

About Mauna Kea Technologies Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.

Disclaimer This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are forward-looking statements. Mauna Kea Technologies believes that these forward-looking statements are based on reasonable assumptions. However, no assurance can be given that the expectations expressed in these forward-looking statements will be achieved. These forward-looking statements are subject to numerous risks and uncertainties, including those described in Chapter 2 of Mauna Kea Technologies' 2023 Annual Report filed with the Autorité des marchés financiers (AMF) on April 30, 2024, which is available on the Company's website (www.maunakeatech.fr), as well as the risks associated with changes in economic conditions, financial markets and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this press release are also subject to risks that are unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not currently consider material. The occurrence of some or all of these risks could cause the actual results, financial condition, performance or achievements of Mauna Kea Technologies to differ materially from those expressed in the forward-looking statements. This press release and the information contained herein do not constitute an offer to sell or subscribe for, or the solicitation of an order to buy or subscribe for, shares of Mauna Kea Technologies in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The distribution of this press release may be restricted in certain jurisdictions by local law. Persons into whose possession this document comes are required to comply with all local regulations applicable to this document.

1 Deposit number US-D1057759

Mauna Kea Technologies

investors@maunakeatech.com

NewCap - Investor Relations

Aurélie Manavarere / Thomas Grojean +33 (0)1 44 71 94 94 maunakea@newcap.eu

Mauna Kea Technologies (EU:ALMKT)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025 Click aqui para mais gráficos Mauna Kea Technologies.
Mauna Kea Technologies (EU:ALMKT)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025 Click aqui para mais gráficos Mauna Kea Technologies.